Search

Displaying results 491 - 500 of 10000 in total
  1. Drug

    Pseudoephedrine

    go.drugbank.com/drugs/DB00852
    Approved

    [A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. … [A188823] The decongestant effect of pseudoephedrine was described in dogs in 1927.[A188823]

    Mixtures: COUGH-EN LINCTUS, COUGH-EN LINCTUSProducts: DEKOFERIN-EX SURUP 150 ML
  2. Indication

    Tuberous Sclerosis Complex with Renal angiomyolipoma

    go.drugbank.com/conditions/DBCOND0025534
    Drugs: Everolimus
    Synonyms: Tuberous Sclerosis Complex with Renal angiomyolipoma
  3. Drug

    Zoledronic acid

    go.drugbank.com/drugs/DB00399
    ApprovedInvestigational

    [L13712,L13715,L13721] Zoledronic acid was first described in the literature in 1994.[A203120] Zoledronic acid was granted FDA approval on 20 August 2001.[L13712]

    Products: ACIDO ZOLEDRONICO SUN PHARMACEUTICAL INDUSTRIES EUROPE BV
  4. Drug

    Paroxetine

    go.drugbank.com/drugs/DB00715
    ApprovedInvestigational

    [L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. … [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.

    Products: PAROXETINA EG, PAROXETINA EG STADA
  5. Drug

    Colloidal oatmeal

    go.drugbank.com/drugs/DB11286
    ApprovedNutraceutical

    It is available in topical products as a skin soothing agent. … Phenols are also contained in colloidal oatmeal, which possess antioxidant and anti-inflammatory activities, as well as UV-absorbing activity.

    Mixtures: Infinite Aloe All-IN-one Skin CareProducts: End-itch, End-itch for Eczema
  6. Drug

    Lorazepam

    go.drugbank.com/drugs/DB00186
    ApprovedInvestigational

    [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. … The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.[L5095]

    Products: LORAZEPAM EG
  7. Target

    Copper-containing nitrite reductase

    go.drugbank.com/bio_entities/BE0001495
    TargetAchromobacter cycloclastes

    Polypeptides: Copper-containing nitrite reductaseFunction: copper ion binding
  8. Target

    Copper-containing nitrite reductase

    go.drugbank.com/bio_entities/BE0002802
    TargetAlcaligenes xylosoxydans xylosoxydans

    Polypeptides: Copper-containing nitrite reductaseSynonyms: Dissimilatory copper-containing nitrite reductase
  9. Target

    Copper-transporting ATPase 2

    go.drugbank.com/bio_entities/BE0003664
    TransporterHumans

    Copper ion transmembrane transporter involved in the export of copper out of the cells. … It is involved in copper homeostasis in the liver, where it ensures the efflux of copper from hepatocytes into the bile in response to copper overload

    Polypeptides: Copper-transporting ATPase 2Synonyms: Copper pump 2
  10. Target

    CMV DNA Terminase Complex

    go.drugbank.com/bio_entities/BE0010221
    TargetHuman Cytomegalovirus

    Forms a tripartite terminase complex together with TRM2 and TRM3 in the host cytoplasm. Once the complex reaches the host nucleus, it interacts with the capsid portal vertex. … Forms a tripartite terminase complex together with TRM1 and TRM3 in the host cytoplasm. Once the complex reaches the host nucleus, it interacts with the capsid portal vertex.